CONTROL Baseline Amiloride Forskolin Inh172 Vte (mV) -78 -2 -4 -3 DVRt (mV) 8 16 7.5 13 R (W.cm-2) 800 1600 750 1300 I (mA.cm-2) 98 1 5 2 CFTR-CRISPR Vte (mV) -38 -6 -23 -9 DVRt (mV) 9 27 6 11 R (W.cm-2) 900 2700 600 1100 I (mA.cm-2) 42 2 38 8 What is the size of the current that flows through ENaC for both vectors and What is the size of the current that flows through CFTR for both vectors?
You are employed in a gene therapy laboratory to test the effectiveness of a vector for correcting the DF508 –CFTR mutation. The vector uses CRISPR –CAS9 genome editing to correct the mutated gene in situ (CFTR-CRISPR). An Ussing chamber experiment was performed using nasal airway cells obtained from a patient with the DF508 CFTR mutation which were transformed with either a control vector consisting of an inert CRISPR-CAS-9 construct (CONTROL) or the active, gene correcting CRISPR CAS-9 construct (CFTR-CRISPR). The following transepithelial voltage values were obtained for the drug regimen shown under open circuit and current clamp (injected current of 10mA) conditions:
|
CONTROL |
|
Baseline |
Amiloride |
Forskolin |
Inh172 |
|
Vte (mV) |
-78 |
-2 |
-4 |
-3 |
|
|
DVRt (mV) |
8 |
16 |
7.5 |
13 |
|
|
R (W.cm-2) |
800 |
1600 |
750 |
1300 |
|
|
I (mA.cm-2) |
98 |
1 |
5 |
2 |
|
|
CFTR-CRISPR |
Vte (mV) |
-38 |
-6 |
-23 |
-9 |
|
DVRt (mV) |
9 |
27 |
6 |
11 |
|
|
R (W.cm-2) |
900 |
2700 |
600 |
1100 |
|
|
I (mA.cm-2) |
42 |
2 |
38 |
8 |
What is the size of the current that flows through ENaC for both vectors and What is the size of the current that flows through CFTR for both vectors?
Step by step
Solved in 2 steps
